Avenue Therapeutics, Inc. (ATXI) OTC
0.24
-0.0375(-13.51%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.24
-0.0375(-13.51%)
Currency In USD
| Previous Close | 0.28 |
| Open | 0.16 |
| Day High | 0.24 |
| Day Low | 0.16 |
| 52-Week High | 0.97 |
| 52-Week Low | 0.15 |
| Volume | 57 |
| Average Volume | 5,260 |
| Market Cap | 764,053 |
| PE | 0.31 |
| EPS | 0.77 |
| Moving Average 50 Days | 0.34 |
| Moving Average 200 Days | 0.54 |
| Change | -0.04 |
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from AxsomeMIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE)
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
GlobeNewswire Inc.
Oct 09, 2024 12:30 PM GMT
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases